WEBULL
WebtradeDownload

Sanofi (ENXTPA:SAN) Could Be 3% Overvalued On Canada Expansion And Portfolio Shift

Simply Wall St · 1d ago

Sanofi (ENXTPA:SAN) just cut the ribbon on the Charles Best Building in Canada, a flu vaccine facility tied to a C$925 million biomanufacturing investment that includes substantial federal and provincial backing.

Sanofi has been busy on multiple fronts, pairing the Charles Best Building opening with a planned partnership that will transfer 20 mature medicines and three manufacturing sites to Cheplapharm in exchange for a sizeable equity stake.

Against that backdrop, the shares closed at €74.59, with a 90-day share price return of 1.52% but a year-to-date share price decline of 9.39%. The 1-year total shareholder return is down 1.83%, suggesting long-term momentum has faded even as recent news has started to reset expectations around the business mix and risk profile.

Spot opportunities around Sanofi by comparing its latest moves with a hand-picked 175 high quality undervalued stocks that may also be reshaping portfolios through focused pipelines and asset realignments.

Sanofi now trades at €74.59 while analyst and intrinsic estimates cluster far higher, leaving a wide span between sticker price and implied worth. How much of that gap looks justified once the numbers are unpacked?

Most Popular Narrative: 3.3% Overvalued

Sanofi is trading at €74.59 while the most followed narrative pegs fair value at €72.23, a small premium that raises questions about how much good news is already in the price.

Der französische Pharmariese Sanofi bietet Anlegern derzeit eine interessante Kombination aus attraktiver Bewertung, starker Dividendenrendite und solider operativer Dynamik.

Wer jedoch ein substanzstarkes, krisenresistentes Unternehmen mit hohen Cashflows und einer starken Dividende sucht, findet in Sanofi derzeit einen attraktiven und fair bewerteten Titel.

See why 2 investors see Sanofi as 3% overvalued.

Result: Fair Value of €72.23 (OVERVALUED)

Still, Sanofi faces real pressure if key drug patents erode faster than expected or if regulatory setbacks slow approvals in its core immunology and vaccine franchises.

Find out about the key risks to this Sanofi narrative.

Another View On Sanofi’s Valuation

On simple P/E, Sanofi trades at 22.7x, which looks rich versus the European pharma average at 20.4x and its peer group on 17x. The fair ratio of 38.1x points to upside if sentiment shifts. However, that gap also reflects real valuation risk if expectations cool.

See what the numbers say about this price — find out in our valuation breakdown.

ENXTPA:SAN P/E Ratio as at Sep 2026
ENXTPA:SAN P/E Ratio as at Sep 2026

Next Steps

Mixed signals around Sanofi's value and risk profile can feel uncomfortable, so move fast, review the data for yourself, and weigh both sides through the 3 key rewards and 3 important warning signs.

Looking for more ideas beyond Sanofi?

If Sanofi is on your radar, do not stop there. Use the screener to surface other opportunities that fit your style before the market prices them in.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.